Drug intelligence / Profile preview

neutral protamine hagedorn

Development stage
Unknown
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting human insulin formulation used to manage blood glucose levels in patients with diabetes mellitus. It is produced by complexing recombinant human insulin with protamine and zinc, which delays its absorption and extends its duration of action to approximately 10–16 hours. In the context of the Assiut University study (NCT03835390), NPH is evaluated as part of a conventional insulin regimen in pregnant women with pre-gestational diabetes. The study compares this conventional approach against basal-bolus regimens using insulin analogues to determine the impact on maternal and fetal outcomes, such as glycemic control and the incidence of macrosomia.

Brand names
Humulin NNovolin NInsuman Basal
Other names
isophane insulinNPH insulinneutral protamine hagedorn-Assiut University-pre-gestational diabetes
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on neutral protamine hagedorn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neutral protamine hagedorn.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call